STAAR Surgical Posts Record Revenue, Returns to Profitability in Q1 2026
Event summary
- STAAR Surgical reported Q1 2026 net sales of $93.5 million, up 119.6% year-over-year, driven by strong performance in China and double-digit growth in the Americas.
- The company returned to profitability with a net income of $5.2 million, compared to a net loss of $54.2 million in the same period last year.
- Gross margin improved to 73.6% from 65.8% a year ago, supported by cost reductions and operational efficiencies.
- STAAR surpassed the milestone of 4 million ICLs sold globally and launched the EVO+ ICL in China, which has seen strong early demand.
- The company is scaling its manufacturing facility in Nidau, Switzerland, to supply 100% of EVO ICL and EVO+ ICL lenses to China without import tariffs.
The big picture
STAAR Surgical's strong Q1 2026 results highlight its strategic focus on revenue growth and profit expansion. The company is well-positioned in the lens-based refractive surgery market, which is gaining momentum as laser-based procedures decline. STAAR's ability to navigate geopolitical uncertainties and sustain its operational improvements will be critical to its long-term success.
What we're watching
- Market Expansion
- Whether STAAR can sustain its growth momentum in China and other key markets amid geopolitical uncertainties.
- Operational Efficiency
- The pace at which STAAR can scale its Swiss manufacturing facility and implement its new ERP system to support future growth.
- Product Innovation
- How the launch of the EVO+ ICL in China will impact margin expansion and surgeon adoption.
Related topics